Abbott Laboratories (ABT)

Abbott’s medical device business includes cardiovascular and neuromodulation products such as pacemakers, implantable cardioverter defibrillators, coronary stents, catheters, and related technologies. It is also a major participant in diabetes care through continuous glucose monitoring systems, an area that has become increasingly important as patients and clinicians adopt more data-driven tools for managing chronic disease.

The diagnostics division supplies laboratory instruments, immunoassays, molecular testing systems, and point-of-care tests used by healthcare providers to detect and monitor disease. Abbott’s nutrition business sells infant formula, pediatric nutrition products, and adult nutritional drinks, giving the company a meaningful presence in both clinical and consumer health channels. Its established pharmaceuticals segment focuses on branded generic medicines, mainly in international markets.

Abbott generates a significant share of its revenue outside the United States, which gives it broad geographic exposure but also subjects results to currency movements, regulation, reimbursement systems, and local market conditions. The company’s distinctive strength is its balanced healthcare model: it is not dependent on a single therapy area or product category, and it combines recurring demand for everyday health products with higher-technology device and diagnostic platforms.